A major concern for me regarding the future for both our Flagship ( Nextellis ) Annovera etc. is their repeated acceptance in the market. Mithra according to their last financial year were virtually entirely dependent on Mayne for revenue. This from a company continuing to portray itself as a Global force in women’s health. Total sales for year €7m. Who the hell do they think they’re kidding. The rest of the world is not buying their Pill. We at Mayne appear to be hugely discounting and buying market share by sales reps training to sell . Problem is do consumers stay converted. ? With Annovera the deal with TXmd was they would assist us with staffing during transition period with sales and we would increase with another $20m sales expense. Although only a short period I know the graph on its sales had a slight decline and appears a hard sell. I hope it’s not another Nextellis. The total existence and forecast growth of Mayne mis dependant upon the success of these two hugely expensive upfront and ongoing products.
MYX Price at posting:
$3.23 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)